

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 May 2008 (15.05.2008)

PCT

(10) International Publication Number  
**WO 2008/055996 A1**

(51) International Patent Classification:  
**A61K 9/28** (2006.01) **A61K 9/48** (2006.01)

(21) International Application Number:  
PCT/EP2007/062180

(22) International Filing Date:  
9 November 2007 (09.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/858,157 10 November 2006 (10.11.2006) US

(71) Applicant (for all designated States except US): **AL-PHAPTOSE GMBH** [DE/DE]; Alsterchaussee 13, 20149 Hamburg (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RICHTER, Wolfgang** [DE/DE]; Leharstrasse 35, 81243 München (DE). **WEBER, Lutz** [DE/DE]; Edelweissstrasse 8, 82110 Gerning (DE).

(74) Agent: **HUENGES, Martin**; Elisenhof, Elisenstrasse 3, 80335 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: ORAL DOSAGE FORM COMPRISING TRI-SUBSTITUTED GLYCEROL COMPOUNDS

(57) Abstract: The present invention relates to pharmaceutical solid dosage forms for oral administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases.



WO 2008/055996 A1

## Oral dosage form comprising tri-substituted glycerol compounds

- The present invention relates to pharmaceutical solid dosage forms for oral
- 5 administration comprising a tri-substituted glycerol compound or a pharmaceutically acceptable salt thereof. The invention also relates to a corresponding method for preparing such dosage forms as well as to their use as medicaments for the treatment of cancer and immune diseases.
- 10 The tri-substituted glycerol compounds used in the present invention belong to the class of synthetic ether-linked alkyl-lysophospholipids. Since these lipids are known to have an anti-cancerogenic activity, they are also collectively named "anti-tumor ether lipids" (reviewed, e.g., by Arthur, G., and Bittman, R. (1998) *Biochim. Biophys. Acta* **1390**, 85-102; Jendrossek, V., and Handrick, R. (2003) *Curr. Med. Chem. Anti-Canc. Agents* **3**, 343-353; Mollinedo, F. et al. (2004) *Curr. Med. Chem.* **11**, 3163-3184).

- Aside from their anti-tumor activity, these ether lipids are believed to be involved in a variety of other physiological processes such as inflammation, the immune
- 20 response or allergic reactions. It is established in the art that these ether lipids can be used as medicaments for the treatment of various immune diseases (cf., for example, the International Patent Applications WO 87/01257 and WO 90/14829, respectively).

- 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine (also referred to as ET-18-OCH<sub>3</sub>, AP-121 or edelfosine) is considered to be the prototype of the anti-tumor ether lipids. 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine represents a synthetic analogue of the platelet activating factor (PAF; 1-*O*-alkyl-2-acetyl-sn-glycero-3-phosphocholine), a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis.
- 30 Unlike most conventional chemotherapeutic drugs, the anti-tumor ether lipids do not directly target cellular DNA but rather affect the plasma membrane lipid composition and/or interfere with various signal transduction pathways. Two major cellular targets of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine have been identified

- 2 -

so far, namely the CTP: phosphocholine cytidylyl-transferase (CCT; EC 2.7.7.15) and the death receptor Fas (also known as APO-1 or CD95). In a recent study, 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine has been further demonstrated to target two different sub-cellular structures in a cell type-dependent manner, namely  
5 cell surface lipid rafts in leukemic cells and the endoplasmic reticulum in solid tumor cells, and to affect processes taking place in both structures that eventually induce lipid raft- and endoplasmic reticulum-mediated cell death, respectively (Nieto-Miguel, T. et al. (2006) *J. Biol. Chem.* **281**, 14833-14840).

10 Cancer chemotherapy generally aims to slow the growth of, or destroy, cancer cells while avoiding collateral damage to surrounding cells and tissues. Consequently, the most effective anticancer agents are those that are able to selectively target cancer cells while leaving normal cells relatively unaffected. Synthetic ether-lipids have been shown to be effective as tumor agents, for example, in order to decrease or to  
15 stop tumor progression, i.e. to stabilize the "status quo" of the condition, or even to reduce the size of tumors in mammals. It has been found that 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine is particularly suitable for the treatment of different types of tumors such as brain tumors or mamma carcinomas (cf., for example, the German Patent DE 2619686 as well as the International Patent  
20 Applications WO 99/59599 and WO 00/01392, respectively).

Several mechanisms of action have been proposed for the toxicity of ether-lipids towards cancer cells, including the cells' lack of alkyl cleavage enzymes. The resultant inability to hydrolyze the ether-lipids leads to their intracellular  
25 accumulation and the consequent damage of cell membrane lipid organization. Other potential mechanisms of ether-lipid action include effects on levels of intracellular protein phosphorylation, and disruption of cellular lipid metabolism. Normal cells typically possess the means to avoid or overcome the potentially toxic effects of ether-lipids, while cancer cells do not.

- 3 -

The anti-tumor activity of these synthetic ether lipids has been experimentally proven in several animal tumor models. However, their clinical use is often hampered by systemic cytotoxic effects including hemolysis (particularly observed in the gastrointestinal tract but also *inter alia* in lung, liver or kidney).

5

1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine and other synthetic ether-lipids can be administered to patients by using the intravenous route. In this context, it was found that the intravenous administration of a liposomal formulation is advantageous in order to improve therapeutic efficacy while markedly reducing nonspecific  
10 toxicity *in vivo* (see, for example, Ahmad, I. et al. (1997) *Cancer Res.* **57**, 1915-1921).

The International Patent Application WO 91/09590 describes a pharmaceutical preparation of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine for intravenous  
15 administration that contains a lipophilic oil-in-water emulsion that can be used to administer high doses of the compound without adverse side effects.

However, it is also known in the art that certain ether phospholipid and carbamoyl salts while exhibiting benefits to a patient as competitive inhibitors of PAF or tumor  
20 growth with single or repeated injections, cause detrimental effects in the area of the injection. These detrimental effects are evident as lysis of red blood cells, severe edema, inflammation, and injection site-necrosis. These adverse effects are also called "detergent" effects. Where repeated injections are required, these detrimental effects are particularly disadvantageous as they render the sites of administration  
25 unsuitable and require fresh sites. Since the number of suitable sites on a patient is limited, it would be highly desirable to avoid said detrimental effects associated with intravenous administration of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine.

More recently, it has been shown that it is also possible to administer 1-*O*-octadecyl-  
30 2-*O*-methyl-glycero-3-phosphocholine orally together with a liquid drinkable

vehicle. In the International Patent Application WO 99/59599, it is described that 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine can be administered together with water-based vehicles containing at least 3% (w/w) fat and/or protein such as soups (especially thickened soups), eggnog and other conventional beverages. Milk-based vehicles are also suitable, such as milk, milk substitute, yogurt, kefir and the like. It is tempting to speculate that an efficient binding of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine to the proteins and/or other lipids "mask" the ether-lipid thus resulting in a reduction of adverse side effects.

10 Nevertheless, in 10-20% of the patients treated with such water- and/or milk-based vehicles significant gastrointestinal incompatibilities (corresponding to WHO toxicity grades III and IV, respectively) have been observed that are associated with loss of appetite, nausea and/or vomiting, diarrhea, constipation or the like (see, e.g., Drings, P. et al. (1992) *Onkologie* **15**, 375-382).

15 Furthermore, notwithstanding the additional problem of food allergies (such as lactose incompatibility) it is also not convenient for a patient to take the medicament with considerable amounts of food or drinks several times a day. Furthermore, it is evident that e.g. a milk-based medicament needs to be prepared every time immediately before administration. This is not only time consuming and non-practical, but may also be an element of uncertainty with respect to the dose amount, since the preparation of the medicament requires accurate weighing and intense mixing. Finally, it must also be ensured that the patient takes the medicament completely to ensure uptake of the complete dose amount.

25 Thus, there still remains a need for an alternative oral dosage form comprising 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine or a related tri-substituted glycerol compound that overcomes the above limitations. In particular, there is a need for a dosage form, which is in solid form, allows for an easy and convenient administration and provides the required pharmaceutical efficacy with respect to the

30

- 5 -

treatment of cancer and other diseases. Since the uptake of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine or related tri-substituted glycerol compounds takes place in the colon, it would be most desirable to have a solid enteric pharmaceutical dosage form that passes the stomach without being disintegrated.

5

Accordingly, it is an object of the present invention to provide such a pharmaceutical solid dosage form for oral administration.

This object is achieved by the pharmaceutical dosage form having the features of independent claim 1. Some of the preferred embodiments of the present invention are defined by the subject matter of the dependent claims.

According to the present invention, it has been found that it is possible to formulate solid oral dosage forms containing tri-substituted glycerol compounds such as 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine which are suitable for treating cancer or immune diseases, and which allow for a precise dosing and a convenient taking of the medicament. The inventive oral dosage form provides the desired efficacy or the required bioavailability of the active agent when administered to patients.

20


In the context of the present invention any numerical value indicated is typically associated with an interval of accuracy that the person skilled in the art will understand to still ensure the technical effect of the feature in question. As used herein, the deviation from the indicated numerical value is in the range of  $\pm 10\%$ , and preferably of  $\pm 5\%$ .

25

In a first aspect, the present invention relates to pharmaceutical solid dosage forms for oral administration comprising a tri-substituted glycerol compound according to formula (I)

30

- 6 -



or an enantiomer or diastereomer or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein

- 5        X is selected from the group consisting of phosphate and sulfate;  
       R<sub>1</sub> is selected from the group consisting of C<sub>16</sub>- C<sub>20</sub> alkyl;  
       R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl and C<sub>1</sub>-C<sub>3</sub>  
       hydroxyalkyl;  
       R<sub>3</sub> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>3</sub> alkyl;
- 10      R<sub>4</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl;  
       and  
       R<sub>5</sub> is selected from the group consisting of hydrogen and methyl.

- 15      The tri-substituted glycerol compound may be present in amorphous or in crystalline  
       form. The term "amorphous", as used herein, refers to a solid in which there is no  
       long-range order of the positions of the atoms, i.e. a non-crystalline material. In  
       preferred embodiments of the invention, the tri-substituted glycerol compound is  
       present in crystalline form.

- 20      The terms "C<sub>n</sub> alkyl", "C<sub>n</sub> hydroxyalkyl", and "C<sub>n</sub> cycloalkyl", as used herein, denote  
       an alkyl group, a hydroxyalkyl group or a cycloalkyl group having n carbon atoms,  
       respectively. For example, the term "C<sub>18</sub> alkyl" refers to an alkyl group having 18  
       carbon atoms. The alkyl groups or hydroxyalkyl groups according to the invention  
       may be straight or branched.

- 7 -

The tri-substituted glycerol compounds of formula (I) have one or more asymmetric centers and thus they can exist as enantiomers or diastereomers. Thus, the pharmaceutical solid dosage forms according to the present invention may comprise either one or more separate individual isomers (such as the L form and the D form)  
5 or mixtures of isomers, preferably racemic mixtures.

In some embodiments of the invention, the tri-substituted glycerol compounds of formula (I) are present in the dosage form as pharmaceutically acceptable salts. Such salts may comprise any pharmaceutically acceptable anion "neutralizing" the positive  
10 charge of the nitrogen (e.g. chloride, bromide or iodide) or any pharmaceutically acceptable cation "neutralizing" the negative charge of the phosphate or sulfate moiety (e.g. sodium or potassium cations).

In a particular preferred embodiment of the present invention, the pharmaceutical  
15 solid dosage form comprises a tri-substituted glycerol compound according to formula (I), wherein X is phosphate, R<sub>1</sub> is  $-(CH_2)_{17}-CH_3$ , R<sub>2</sub> is CH<sub>3</sub>, R<sub>3</sub> is H, R<sub>4</sub> is  $-(CH_2)_2-$ , and R<sub>5</sub> is CH<sub>3</sub>.

According to the present invention, it is to be understood that the tri-substituted  
20 glycerol compound is present in the pharmaceutical solid dosage form in any amount being effective to achieve the desired pharmacological effect such as to stop tumor progression or to induce an apoptotic effect in tumor cells when administered to a patient. Effective amounts are generally chosen in accordance with a number of factors, e.g., the age, size and general condition of the patient and the medical  
25 condition being treated, and determined by a variety of means, for example, dose ranging trials, well known to, and readily practiced by persons of ordinary skill in art given the teachings of this invention.

Typically, in the pharmaceutical dosage form according to the present invention the  
30 amount of the tri-substituted glycerol compound according to formula (I) is less than

- 8 -

400 mg, preferably it is in the range of 30 to 250 mg, and most preferably it is in the range of 50 to 150 mg. In particularly preferred embodiments of the invention, the amount of the tri-substituted glycerol compound according to formula (I) is 75 mg and 100 mg, respectively.

5

The daily dosage of the tri-substituted glycerol compound administered to a patient is less than 1200 mg, typically less than 900 mg, preferably in the range of 30 to 600 mg, more preferably in the range of 40 to 400 mg, and most preferably in the range of 50 to 350 mg. In specific embodiments, the daily dosage is 75, 100, 150, 200, 225, and 300 mg. Preferably, the daily dosage of the tri-substituted glycerol compound is administered as a single dose such as in form of one up to four tablets or capsules. However, it may also be possible to administer the compound in multiple doses such as two or three individual doses administered during the day, e.g. in the morning, at noon, and at night.

15

Typically, the pharmaceutical solid dosage form according to the present invention has a total weight of at least 1600 mg. Preferably, the total weight of the dosage form is in the range of 200 to 1200 mg, more preferably in the range of 250 to 1000 mg and most preferably in the range of 300 to 800 mg. The diameter of the solid dosage form is typically at least 17 mm. Preferably, the diameter of the dosage form is in the range of 9 to 15 mm, and particularly preferably in the range of 11 to 12 mm.

20

The tri-substituted glycerol compound according to formula (I) may be present in the pharmaceutical solid dosage form as a single active ingredient or in combination with at least one other active ingredient such as chemotherapeutics or monoclonal antibodies.

25

Furthermore, it is known that the absorption and bioavailability of any particular therapeutic agent can be affected by numerous factors when dosed orally. Such factors include the presence of food in the gastrointestinal (GI) tract because, in

30

- 9 -

general, the gastric residence time of a drug is usually significantly longer in the presence of food than in the fasted state. If the bioavailability of a drug is affected beyond a certain point due to the presence of food in the GI tract, the drug is said to exhibit a "food effect" or show a drug/food interaction. This factor should be taken  
5 into consideration when choosing the dose amount.

The term "pharmaceutically acceptable excipient" in the meaning of the present invention can be any substance used for the preparation of pharmaceutical dosage forms such as coating materials, film-forming materials, fillers, disintegrating agents,  
10 release-modifying materials, carrier materials, diluents, binding agents and other adjuvants.

The term "pharmaceutical solid dosage form for oral application" according to the present invention refers to any pharmaceutical formulation suitable for oral  
15 application. Examples of such dosage forms include *inter alia* tablets, pills, capsules, granulates, pellets, powders, multi-particulate formulations (e.g., beads, granules or crystals) and dragees.

All these dosage forms are well established in the art (see, e.g., Gennaro, A.L. and  
20 Gennaro, A.R. (2000) *Remington: The Science and Practice of Pharmacy*, 20th Ed., Lippincott Williams & Wilkins, Philadelphia, PA; Ritschel, W.A. & Bauer-Brandl, A. (2002) *Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung*. Editio-Cantor Verlag, Aulendorf, Germany; Crowder, T.M. et al. (2003) *A Guide to Pharmaceutical Particulate Science*. Interpharm/CRC, Boca  
25 Raton, FL; Niazi, S.K. (2004) *Handbook of Pharmaceutical Manufacturing Formulations*, CRC Press, Boca Raton, FL).

In preferred embodiments of the invention, the pharmaceutical solid dosage form is selected from the group consisting of tablets, pills, capsules, and granules, with  
30 tablets being particularly preferred.

In another preferred embodiment of the invention, the solid dosage form is an enteric dosage form, i.e. the dosage form remains stable in the stomach, i.e. in an highly acidic environment. This may be achieved by providing a solid dosage form  
5 comprising a film coating.

Thus, in further embodiments of the invention, the solid dosage form comprises a film coating. For example, the inventive dosage form may be in the form of a so-called film tablet. The inventive dosage may comprise two or more film coating  
10 layers. The corresponding dosage form may be a bilayer or multilayer tablet. The film coating may have a thickness of about 20 microns to about 1200 microns.

Methods for the preparation of film coated dosage forms are well established in the art (see, for example, Gennaro, A.L. and Gennaro, A.R. (2000) *Remington: The  
15 Science and Practice of Pharmacy*, 20th Ed., Lippincott Williams & Wilkins, Philadelphia, PA; Ritschel, W.A. & Bauer-Brandl, A. (2002) *Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung*. Editio-Cantor Verlag, Aulendorf, Germany; Crowder, T.M. et al. (2003) *A Guide to  
Pharmaceutical Particulate Science*. Interpharm/CRC, Boca Raton, FL; Niazi, S.K.  
20 (2004) *Handbook of Pharmaceutical Manufacturing Formulations*, CRC Press, Boca Raton, FL). It is also well-known in the art how to provide film coatings with specific properties, like enteric coatings, film coating which dissolve upon contact with body fluids, controlled release coatings, taste-masking coatings or disintegrating coatings. In a particularly preferred embodiment, the solid dosage form of the  
25 invention comprises an enteric coating.

Typically, the film coating comprises at least one film forming material in an amount of up to 85 % (w/w), based on the total weight of the film coating. In preferred embodiments, the film forming material is selected from the group consisting of  
30 acrylic resins such as Eudragit™ polymers (Röhm GmbH & Co. KG, Darmstadt,

Germany), polymethacrylate derivatives, gelatin, polyvinyl pyrrolidone, methylcellulose, ethylcellulose, carboxy methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, and polyvinyl acetate phthalate or mixtures thereof, with hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinyl acetate phthalate acrylic resins and Eudragit™ polymers being particularly preferred. Preferred Eudragit™ polymers are selected from the group consisting of Eudragit™ L30 D-55, L100-55, L100, L12.5, S100, and S12.5.

10

The film coating or film coating material according to the present invention may comprise at least one plasticizer. The amount of plasticizer in the film coating material is typically in the range of about 3% (w/w) to 30% (w/w), based on the total weight of the film coating. Suitable plasticizers according to the present invention are selected from the group comprising polyethylene glycol, polyethylene oxide, and triethyl citrate.

15

The film coating may also comprise at least one stabilizer. Usually, stabilizers are wetting agents such as sorbitol, polyethylene glycol, polyvinyl pyrrolidone or detergents such as sodium lauryl sulfate, e.g. Texapon K12 (Cognis Deutschland GmbH & Co. KG, Düsseldorf, Germany). The stabilizer is typically contained in the film coating material in an amount of about 1% (w/w) to 5% (w/w), based on the total weight of the film coating.

20

Furthermore, the film coating may also comprise at least one separating agent or anti-adherent. Usually, separating agents are inert compounds such as magnesium/aluminum silicate or metal soaps such as talcum and magnesium stearate. Usually, the amount of separating agent in the film coating material is in the range of about 1% (w/w) to 5% (w/w), based on the total weight of the film coating.

25

30

Optionally, the film coating may also comprise pigments for coloring such as titanium oxide, red ferrous oxide or yellow ferrous oxide. Typically, such pigments are present in the film coating material in an amount of up to 1% (w/w), based on the total weight of the coating.

5

In another preferred embodiment of the present invention, the enteric film coating of the pharmaceutical solid dosage form is soluble at a pH  $\geq 6.8$ , preferably at a pH  $\geq 5.5$ . It is also preferred that the pharmaceutical solid dosage form according to U.S. Pharmacopoeia XXIX <701> disintegrates at a pH in the range of  $\geq 6.8$  within a  
10 contact time of at last 30 minutes (i.e. when in contact with intestinal fluid), preferably within a contact time of at last 15 minutes.

It is further preferred that the pharmaceutical solid dosage form according to U.S. Pharmacopoeia XXIX <701> does not disintegrate at a pH in the range of  $\leq 2.5$   
15 within a contact time of at least 120 minutes (i.e. when in contact with gastric fluid).

According to the present invention, the solid dosage form may comprise up to 50 % (w/w) of the at least one excipient, wherein the excipient preferably comprises at least one filler, at least one binder, at least one disintegrating agent, at least one  
20 flowability-controlling agent, and at least one lubricant.

The term "filler", as used herein, refers to inert compounds that may be present in the pharmaceutical solid dosage form of the invention in an amount of up to 70% (w/w), based on the total weight of the dosage form. Examples of suitable filler include *inter*  
25 *alia* lactose, glucose, fructose, calcium hydrogenphosphate (dihydrate), pectin, alginate, starch (e.g., corn starch), microcrystalline cellulose as well as 1:1 mixtures each two of lactose, calcium hydrogenphosphate, microcrystalline cellulose, and corn starch, respectively.

- 13 -

The term "binder", as used herein, refers to an excipient, which is suitable for binding other components to one another. Suitable binders include *inter alia* glucose, dextrin, maltodextrin, methylcellulose, ethylcellulose, hydroxyethyl cellulose, magnesium aluminium silicate, guar gum, polyvinyl pyrrolidone, polyethylene oxide, 5 gelatin, sodium alginate and hydrogenated vegetable oils. Such binders may be present in the dosage form of the invention in an amount of 1% (w/w) to 15% (w/w), based on the total weight of the dosage form.

10 In addition, the inventive dosage form may also contain one or more lubricants (glidants) such as magnesium stearate, sodium stearyl fumarate, stearic acid, and glyceryl palmitostearate in an amount of up to 1% (w/w) based on the total weight of the dosage form.

15 The dosage form may further comprise at least one disintegrating agent such as cross-linked sodium carboxymethyl cellulose (croscarmellose sodium), cross-linked polyvinyl pyrrolidone, corn starch, and sodium glycol starch. Such disintegrating agents may be present in the dosage form in an amount in the range of 0.5% (w/w) to 4% (w/w), based on the total weight of the dosage form.

20 The inventive dosage form may also comprise one or more flowability-controlling agents. In preferred embodiments of the invention, the flowability-controlling agent is selected from the group consisting of disperse or colloidal silicon dioxide such as Aerosil™ 200 or Syloid™ 244 (both of Degussa AG, Düsseldorf, Germany), magnesium stearate, calcium arachinate, cetyl alcohol, myristyl alcohol, and 25 mixtures thereof, with silicon dioxide being particularly preferred. Such flowability-controlling agents may be present in the dosage form in an amount of up to 1% (w/w), based on the total weight of the dosage form.

30 In particularly preferred embodiments of the present invention, the ratio between the tri-substituted glycerol compound and the at least one flowability-controlling agent is

- 14 -

1 part by weight of the tri-substituted glycerol compound to 0.01-0.1 parts by weight of the flowability-controlling agent

Furthermore, it may be desirable to provide controlled release dosage forms that  
5 release the tri-substituted glycerol compounds of the invention at a constant rate over a defined period of time. A range of matrix forming natural and synthetic polymers is available to prolong or modify drug release, like for example, xanthan gum, galactomannan polymers, alginate, cellulose derivatives (methylcellulose, hydroxypropyl cellulose and hydroxypropyl methylcellulose etc.), acrylic and  
10 methacrylic co-polymers and combinations thereof. This range of polymers enables formulators to obtain the desired release profile.

Alternatively, the inventive dosage form may contain one or more excipients which are suitable for regulating or modifying the release of the tri-substituted glycerol  
15 compounds of the invention. Suitable excipients for regulating or modifying the release of the tri-substituted glycerol form are hydrophobic release controlling agents and/or hydrophilic polymers.

The hydrophobic release controlling agents may preferably be selected from the  
20 group comprising ammonium methacrylate copolymers, methacrylic acid copolymer, polyacrylate, polyvinyl acetate, ethylcellulose, cellulose acetate, cellulose propionate, cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate phthalate, cellulose triacetate, poly(methyl methacrylate), poly(ethyl methacrylate), poly(butyl methacrylate), poly(isobutyl methacrylate), poly(hexyl methacrylate),  
25 poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate), waxes, fatty alcohols, fatty acid esters and hydrogenated castor oil.

- 15 -

The inventive dosage form may also contain an extended release polymer layer with a hydrophilic polymer being selected from the group comprising carboxymethyl cellulose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methylcellulose and povidone. Alternatively, the dosage form may contain an extended release polymer layer with a hydrophobic material being selected from the group consisting of carnauba wax, ethylcellulose, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, microcrystalline wax, polymethacrylate and stearic acid.

10 In a particularly preferred embodiment of the present invention, the pharmaceutical solid dosage form provides for immediate release of the tri-substituted glycerol compound upon being dissolved and/or disintegrated. It is desirable that the inventive pharmaceutical dosage form provides a defined, preferably rapid release profile. More precisely, the inventive dosage form may be formulated such that at  
15 least 80%, preferably at least 85%, of the total amount of the tri-substituted glycerol compound comprised in the dosage form is released from the dosage form within 45 minutes, preferably within 30 minutes, when measured in a type 1 dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXIX <724> at  $37^{\circ}\text{C} \pm 0.5^{\circ}\text{C}$  in buffer state at pH 6.8 and 75 rotations per minute and/or may be formulated such  
20 that not more than 10% of the total amount of the tri-substituted glycerol compound comprised in the dosage form is released from the dosage form within two hours when measured in a type 1 dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXIX <724> at  $37^{\circ} \pm 0.5^{\circ}\text{C}$  in acidic state at pH 1.2 and 75 rotations per minute.

25

According to another aspect of the present invention, the active agent, the tri-substituted glycerol compound may be contained or dispersed in a matrix being part of the dosage form. The matrix of the inventive dosage form may preferably be an immediate release matrix, although also normal release or controlled release matrices  
30 having a coating that controls the release of the drug may be used.

Suitable materials for a controlled release matrix or coating comprise:

- (i) Hydrophilic polymers, such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred. The dosage form may comprise between 1% and 80% (by weight) of at least one hydrophilic or hydrophobic polymer.
- (ii) Digestible, long chain ( $C_8$ - $C_{50}$ , especially  $C_{12}$ - $C_{40}$ ), substituted or unsubstituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils and waxes. Hydrocarbons having a melting point of between  $25^{\circ}\text{C}$  and  $90^{\circ}\text{C}$  are preferred. Fatty (aliphatic) alcohols are particularly preferred. The dosage form may comprise up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
- (iii) Polyalkylene glycols. The dosage form may comprise up to 60% (by weight) of at least one polyalkylene glycol.

15

Alternatively, the inventive dosage form may comprise a normal release matrix having a coat that controls the release of the tri-substituted glycerol compound. In some embodiments of the invention, the dosage form may comprise film coated spheroids or granules comprising the tri-substituted glycerol compound and a non-water soluble spheronising agent. The term "spheroid" is known in the pharmaceutical art and denotes a spherical granule having a diameter of between 0.5 mm and 2.5 mm especially between 0.5 mm and 2 mm.

20

According to another aspect of the present invention, the dosage form may be a multi-particulate containing formulation. The unit doses of multi-particulates may then be incorporated into a pharmaceutical solid dosage formulation, e.g. via compression or shaping into tablets or by placing a requisite amount inside a gelatin capsule. The multi-particulate dosage forms may comprise coated microparticles, like crystals, granules, pellets or beads.

30

- 17 -

In a second aspect, the present invention relates to a tri-substituted glycerol compound as defined herein for use as a pharmaceutical solid dosage form for oral administration.

- 5 In preferred embodiments, the tri-substituted glycerol compound is for the treatment of cancer or for the treatment of immune diseases (cf. also the definitions indicated below).

10 In a third aspect, the present invention relates to a method for preparing a pharmaceutical solid dosage form as defined herein, the method comprising mixing the tri-substituted glycerol compound with the at least one excipient.

15 In one embodiment of the invention, the method further comprises drying the mixture. In another embodiment, the method further comprises granulating the mixture obtained.

In a preferred embodiment of the invention relating to the preparation of tablets, the method further comprises compressing the, optionally granulated, mixture by using a suitable tablet press. It is particularly preferred to perform compression of the  
20 granulate at a pressure of at least 200 MPa.

Preferably, the at least one excipient comprising fillers, binders, disintegrating agents flowability-controlling agents, lubricants and/or other additives are present in pre-grained form. It is well known to a person of skill in the art how to prepare such pre-grained additives (cf. also the references cited below).  
25

The manufacture of the pharmaceutical solid dosage forms typically occurs at a temperature between 15°C and 26°C, preferably between 18°C and 22°C. The relative humidity in the production rooms is less than 55%, preferably less than 40%.  
30

In another preferred embodiment of the invention, the residual moisture of the final mixture after drying and/or granulating is less than 1.5% (w/w), particularly preferably less than 1.0% (w/w), most preferably less than 0.5% (w/w) based on the total weight of the mixture, respectively.

5

The method according to the present invention is also preferred to comprise coating the pharmaceutical formulation obtained with a film coating material, particularly preferably with an enteric film coating material.

- 10 Methods for preparing pharmaceutical solid dosage forms according to the present invention are well known in the art (see, for example, Gennaro, A.L. and Gennaro, A.R. (2000) *Remington: The Science and Practice of Pharmacy*, 20th Ed., Lippincott Williams & Wilkins, Philadelphia, PA; Ritschel, W.A. & Bauer-Brandl, A. (2002) *Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung*. Editio-Cantor Verlag, Aulendorf, Germany; Crowder, T.M. et al. (2003) *A Guide to Pharmaceutical Particulate Science*. Interpharm/CRC, Boca Raton, FL; Stricker, H. (2003) *Arzneiformenentwicklung*, Springer Verlag, Berlin, Germany; Niazi, S.K. (2004) *Handbook of Pharmaceutical Manufacturing Formulations*, CRC Press, Boca Raton, FL).

20

In a forth aspect, the invention relates to the use of the pharmaceutical solid dosage form, as defined herein, as a medicament for the treatment of cancer or the treatment of immune diseases.

- 25 The term "cancer", as used herein, denotes any type or form of malignant growth of cells or tissues including *inter alia* breast cancer, colorectal cancer, prostate cancer, leukemia, lymphomas, melanoma, and lung cancer. Within the scope of the present invention, the term "cancer" refers to a group of diseases in which cells are aggressive (i.e. they grow and divide regardless of normal limits), invasive (i.e. they invade and destroy adjacent tissues), and metastatic (i.e. they spread to other
- 30

locations in the body). These three "malignant properties" of cancers differentiate them from benign tumors which are self-limited in their growth and do not invade or metastasize (although some benign tumor types are capable of becoming malignant).

- 5 The term "immune disease", as used herein, refers to any disorder of the immune system. Examples of such immune diseases include *inter alia* immunodeficiencies (i.e. congenital or acquired conditions in which the immune system's ability to fight infectious diseases is compromised or entirely absent such as AIDS or SCID), hypersensitivity (such as and forms of allergies or asthma), and autoimmune
- 10 diseases. The term "autoimmune disease" is to be understood to denote any disorder arising from an overactive immune response of the body against endogenic substances and tissues, wherein the body attacks its own cells. Examples of autoimmune diseases include *inter alia* multiple sclerosis, Crohn's disease, lupus erythematosus, myasthenia gravis, rheumatoid arthritis, and polyarthritis.

15

The invention is further described by the following figures and examples, which are solely for the purpose of illustrating specific embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.

- 20 Materials used in tests below are either commercially available or easily prepared from commercially available materials by those skilled in the art.

## **FIGURES**

- 25 **Figure 1** depicts the results of differential scanning calorimetry (DSC) analyses for determining excipient compatibility using a Netzsch DSC 204 apparatus (Netzsch Gerätebau GmbH, Selb, Germany) with a heating rate of 5 K/min up to 300°C and a cooling rate of 1 K/min down to -30°C (temperature onset at room temperature (approx. 20°C)). The below-
- 30 mentioned samples were tested: crystalline 1-*O*-octadecyl-2-*O*-methyl-

glycero-3-phosphocholine alone (black curves), the following excipients alone (red curves): lactose (**Fig. 1A**), crospovidone (**Fig. 1B**), starch 1500 (**Fig. 1C**), siliciumdioxide (**Fig. 1D**), as well as magnesium stearate (**Fig. 1E**), and binary mixtures of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine and each excipient (green curves).

**Figure 2** depicts tablets comprising 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine according to the present invention. **Fig. 2A** shows granulated tablets prepared as described in example 6. The tablets were compressed in a Korsch eccentric press EKO or XP1 (Korsch AG, Berlin, Germany) in different hardness grades (i.e. breaking strength), namely a hardness of 30 N (left) and a hardness of 90 N (right). The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 20% (w/w) based on the total weight of the tablets. **Fig. 2B** shows tablets obtained by direct compression as described in example 4. The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 15% (w/w) based on the total weight of the tablets. The tablets were compressed in a Korsch eccentric press EKO or XP1 (Korsch AG, Berlin, Germany) in a hardness grade of 90 N.

**Figure 3** depicts the *in vitro* effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine (final concentration 10  $\mu$ M), (ionizing) radiation (absorbed dose of 5 Gray units; indicated as "RT"), and a combination thereof on programmed cell death (apoptosis) and the survival rate of LNCaP androgen-sensitive human prostate adenocarcinoma cells. Apoptosis was determined using the Apo-ONE™ Homogenous Caspase-3/7 Assay, Promega, Inc., Madison, WI, USA according to the manufacturer's instructions. The percentage of living cancer cells was estimated by means of trypan blue dye exclusion as described (Freshney, R.I. (1994) *Culture of Animal Cells: A Manual of Basic Technique*. 3rd

Ed. Wiley-Liss. New York. USA) The cells were exposed to radiation six hours after (**Fig. 3A**), concomitantly with (**Fig. 3B**), or six hours before administration of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phospho-choline (**Fig. 3C**). The caspase assay was performed 12 hours after exposure to radiation. The respective data shown represent the average of two independent experiments.

**Figure 4** depicts the *in vivo* effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine (30 mg/kg body weight/day administered intraperitoneally for 15 days; **Fig. 4A**), (ionizing) radiation (absorbed dose of 5 Gray units administered on day 7; **Fig. 4C**), and a combination thereof (**Fig. 4B**) on LNCaP cells grown orthotopically in the prostates of nude mice (seven mice/group). Tumor growth was assessed via determining the serum level of the prostate-specific antigen (PSA) using a commercially available test kit as well as the tumor volume by means of magnetic resonance imaging.

## **EXAMPLES**

The methods for preparing the pharmaceutical solid dosage forms according to the present invention follow establish standard methods well known in the pharmaceutical art (see, for example, the following textbooks: Gennaro, A.L. and Gennaro, A.R. (2000) *Remington: The Science and Practice of Pharmacy*, 20th Ed., Lippincott Williams & Wilkins, Philadelphia, PA; Ritschel, W.A. & Bauer-Brandl, A. (2002) *Die Tablette: Handbuch der Entwicklung, Herstellung und Qualitätssicherung*. Editio-Cantor Verlag, Aulendorf, Germany; Crowder, T.M. et al. (2003) *A Guide to Pharmaceutical Particulate Science*. Interpharm/CRC, Boca Raton, FL; Stricker, H. (2003) *Arzneiformenentwicklung*, Springer Verlag, Berlin, Germany; Niazi, S.K. (2004) *Handbook of Pharmaceutical Manufacturing Formulations*, CRC Press, Boca Raton, FL).

**Example 1: Preparation of an inventive tablet by direct compression**

For the preparation of an inventive tablet by direct compression the following  
5 ingredients were mixed (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	325.0 mg	lactose
	20.0 mg	Kollidon™ VA 64 (BASF, Ludwigshafen, Germany)
	4.0 mg	Aerosil™ 200 (Degusta, Düsseldorf, Germany)
10	2.4 mg	magnesium stearate
	6.0 mg	stearic acid
	4.0 mg	corn starch

Subsequently, the mixture was directly compressed in a tablet press.

15 **Example 2: Preparation of an inventive tablet by direct compression**

For the preparation of an inventive tablet by direct compression the following  
ingredients were mixed (per dosage form):

	90.7 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
20	1.4 mg	formaldehyde casein
	1.4 mg	potato starch
	1.4 mg	gel forming agent from red algae
	1.4 mg	sodium cellulose glycolate
	3.2 mg	stearin talcum
25	0.5 mg	Aerosil™ 200 (Degusta, Düsseldorf, Germany)

Subsequently, the mixture was directly compressed in a tablet press.

**Example 3: Preparation of an inventive tablet by direct compression**

- 23 -

For the preparation of an inventive tablet by direct compression the following ingredients were mixed (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	200.3 mg	calcium hydrogenphosphate
5	200.3 mg	microcrystalline cellulose
	15.0 mg	Kollidon™ CL (BASF, Ludwigshafen, Germany)
	9.4 mg	magnesium stearate

Subsequently, the mixture was directly compressed in a tablet press.

#### 10 **Example 4: Preparation of an inventive tablet by direct compression**

For the preparation of an inventive tablet by direct compression the following ingredients were mixed (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
15	196.3 mg	dicalcium phosphate
	196.3 mg	Avicel™ PH-102 (FMC BioPolymer, Philadelphia, USA)
	20.0 mg	Crospovidone™ (BASF, Ludwigshafen, Germany)
	12.4 mg	magnesium stearate

- 20 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine, Avicel, and dicalcium phosphate were passed through a sieve having a pore size of IV (about 1 mm) and thoroughly mixed. Crospovidone and magnesium stearate were also sieved and admixed. Subsequently, the tablets were compressed in a Korsch eccentric press EKO or XP1 (Korsch AG, Berlin, Germany; the compression forces used were
- 25 between 5 kN and 20 kN) in a hardness grade (i.e. breaking strength) of 90 N.

The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 15% (w/w) (i.e. 75 mg) based on the total weight of the tablets (i.e. 500 mg).

- 30 Analogously, tablets having a total weight of, for example, 300 mg, 350 mg, 375 mg, 400 mg, and 450 mg were prepared (not shown). The tablets have an average

diameter of about 12 mm and an average thickness of about 3 mm to about 5 mm.  
The tablets obtained are shown in Fig 2B.

**Example 5: Preparation of an inventive granulated tablet**

5

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	357.7 mg	lactose
10	40.0 mg	Polyplasdone™ XL (BASF, Ludwigshafen, Germany)
	2.4 mg	magnesium stearate

Subsequently, the mixture was compressed in a tablet press.

**Example 6: Preparation of an inventive granulated tablet**

15

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	249.5 mg	microcrystalline cellulose
20	12.5 mg	Kollidon™ 25 (BASF, Ludwigshafen, Germany)
	30.0 mg	Crospovidone™ (BASF, Ludwigshafen, Germany)
	8.0 mg	magnesium stearate

1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine, and microcrystalline cellulose  
25 were passed through a sieve having a pore size of IV (about 1 mm) and thoroughly mixed. Kollidon was added as a 20% (w/v) solution in isopropanol and granulated. The granulated mixture (representing the inner phase of the tablet) was dried to a residual moisture of less than 3% (w/w) based on the total weight of the mixture (determined using the Ohaus Moisture Analyzer (Ohaus Corp., Pine Brook, NJ,  
30 USA).

- 25 -

Crospovidone and magnesium stearate (representing the outer phase of the tablet) were added. Subsequently, the tablets were compressed in a Korsch eccentric press EKO or XP1 (Korsch AG, Berlin, Germany; the compression forces used were  
 5 between 5 kN and 20 kN) in different hardness grades (i.e. breaking strength) of 30 N (left) and 90 N (right).

The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 20% (w/w) based on the total weight of the tablets (i.e. 300-350 mg). Analogously,  
 10 tablets having a total weight of, for example, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, and 750 mg were prepared (not shown). The tablets have an average diameter of about 12 mm and an average thickness of about 3 mm to about 5 mm depending on the hardness grade. The tablets obtained are shown in Fig 2A.

#### 15 **Example 7: Preparation of an inventive granulated tablet**

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

20	150.0 mg (30.0% w/w)	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	158.8 mg (31.5% w/w)	FlowLac™ 100 (Meggler Pharma, Wasserburg, Germany) (lactose monohydrate)
	158.8 mg (31.5% w/w)	Avicel™ PH-102 (FMC BioPolymer, Philadelphia, USA) (microcrystalline cellulose)
25	20.0 mg (4.0% w/w)	Crospovidone™ (BASF, Ludwigshafen, Germany)
	12.4 mg (3.0% w/w)	magnesium stearate

- 26 -

The tablets were prepared in analogy to example 6. The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 30% (w/w) based on the total weight of the tablets (i.e. 500 mg). The tablets have an average hardness degree (i.e. breaking strength) of about 85 N, an average diameter of about 12 mm and an average thickness of about 5.6 mm.

For the preparation of an alternative inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

10	150.0 mg (25.0% w/w)	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	205.5 mg (34.0% w/w)	FlowLac™ 100 (Meggler Pharma, Wasserburg, Germany) (lactose monohydrate)
	205.5 mg (34.0% w/w)	Avicel™ PH-102 (FMC BioPolymer, Philadelphia, USA) (microcrystalline cellulose)
15	24.0 mg (4.0% w/w)	Crospovidone™ (BASF, Ludwigshafen, Germany)
	15.0 mg (3.0% w/w)	magnesium stearate

The tablets were prepared in analogy to example 6. The amount of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the tablets is 25% (w/w) based on the total weight of the tablets (i.e. 600 mg). The tablets have an average hardness degree (i.e. breaking strength) of about 86 N, an average diameter of about 13 mm and an average thickness of about 6.1 mm.

#### **Example 8: Preparation of an inventive granulated tablet**

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

30	20.0% (w/w)	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
----	-------------	---

- 27 -

- ad 100.0% (w/w) lactose
- 9.2% (w/w) Avicel™ PH-101 (FMC BioPolymer, Philadelphia, USA)
- 15.0% (w/w) saccharose
- quantum satis 15% (w/v) gelatine
- 5 0.5% (w/w) magnesium stearate
- 2.0% (w/w) sodium glycol starch

Subsequently, the mixture was compressed in a tablet press.

#### **Example 9: Preparation of an inventive granulated tablet**

10

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

- 20.0% (w/w) 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine
- ad 100.0% (w/w) lactose
- 15 30.0% (w/w) Avicel™ PH 101 (FMC BioPolymer, Philadelphia, USA)
- 10.0% (w/w) corn starch
- quantum satis 10% (w/v) Kollidon™ 25 (BASF, Ludwigshafen, Germany)
- 1.0% (w/w) Kollidon™ CL (BASF, Ludwigshafen, Germany)
- 2.0% (w/w) magnesium stearate

20 Subsequently, the mixture was compressed in a tablet press.

#### **Example 10: Preparation of an inventive granulated tablet**

For the preparation of an inventive granulated tablet the following ingredients were

25 mixed and granulated (per dosage form):

- 75.0 mg 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine
- 275.0 mg lactose
- 25.0 mg corn starch
- quantum satis 10% (w/v) Kollidon™ 25 (BASF, Ludwigshafen, Germany)
- 30 1.5 mg Aerosil™ 200 (Degusta, Düsseldorf, Germany)

- 28 -

3.0 mg          magnesium stearate

Subsequently, the mixture was compressed in a tablet press.

**Example 11: Preparation of an inventive granulated tablet**

5

For the preparation of an inventive granulated tablet the following ingredients were mixed and granulated (per dosage form):

	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	250.0 mg	lactose
10	25.0 mg	sodium glycol starch
	quantum satis	10% (w/v) Kollidon™ 25 (BASF, Ludwigshafen, Germany)
	0.5 mg	Aerosil™ 200 (Degusta, Düsseldorf, Germany)
	0.5 mg	magnesium stearate

Subsequently, the mixture was compressed in a tablet press.

15

**Example 12: Preparation of enteric pellets according to the invention**

For the preparation of enteric pellets the following ingredients were mixed and granulated (per dosage form):

20	75.0 mg	1- <i>O</i> -octadecyl-2- <i>O</i> -methyl-glycero-3-phosphocholine
	187.0 mg	Avicel™ PH 101 (FMC BioPolymer, Philadelphia, USA)
	13.0 mg	GranuLac™ 140 (Meggler Pharma, Wasserburg, Germany)
	35.0 mg	Eugradit™ L30 D-55 (Röhm GmbH & Co. KG, Darmstadt, Germany)
25	3.4 mg	triethyl citrate
	17.0 mg	magnesium stearate

**Example 13: Preparation of enteric tablets according to the invention**

The tablets prepared according to Examples 1 to 9 were coated with an enteric film coating using established standard methods well known in the art (see the references cited above). The following film coatings were used (the amounts of the respective ingredients are given in mg for tablets having a total weight of 300, 400, 500, 600, 700, and 800 mg, respectively):

**Coating 1:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L30 D-55	12	16	20	24	28	32
Sicopharm™ Yellow 10 (Degussa AG, Düsseldorf, Germany)	1.75	2.3	2.95	3.5	3.95	4.6
Kollidon™ K90	0.4	0.55	0.65	0.8	0.95	1.1

**Coating 2:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L100	12	16	20	24	28	32
Triethyl citrate	2.4	3.2	4.0	4.8	5.6	6.4

10

**Coating 3:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L100	12	16	20	24	28	32
Diethyl citrate	2.4	3.2	4.0	4.8	5.6	6.4
Talcum	2.95	3.9	4.9	5.9	6.9	7.85

**Coating 4:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L100	12	16	20	24	28	32
Triethyl citrate	1.2	1.6	2.0	2.4	2.8	3.2
Talcum	16.8	22.4	28	33.6	31.9	49.8
Magnesium stearate	2.4	3.2	4.0	4.8	5.6	6.4
Titanium dioxide	7.2	9.6	12	14.4	16.8	19.2
Yellow pigment E 104	7.2	9.6	12	14.4	16.8	19.2

- 30 -

(Degusta AG, Düsseldorf, Germany)						
PEG 6000	2.4	3.2	4.0	4.8	5.6	6.4

**Coating 5:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L30 D-55	12	16	20	24	28	32
Talcum	2.95	3.9	3.95	5.9	6.85	7.8
PEG 6000	1.2	1.6	2.0	2.4	2.8	3.2
Anti-foaming emulsion	0.14	0.19	0.23	0.28	0.33	0.38

**Coating 6:**

Total weight tablet	300	400	500	600	700	800
Hydroxypropyl methylcellulose phthalate	12	16	20	24	28	32
Triacetine	1.7	2.35	2.85	3.45	4.0	4.55

5

**Coating 7:**

Total weight tablet	300	400	500	600	700	800
Cellulose acetate phthalate	12	16	20	24	28	32
Triacetine	2.4	3.2	4.0	4.8	5.6	6.4

**Coating 8:**

Total weight tablet	300	400	500	600	700	800
Eudragit™ L30 D-55	12	16	20	24	28	32
Triethyl citrate	1.2	1.6	2.0	2.4	2.8	3.2
Talcum	6	8	9	12	14	16
Titanium dioxide	1.2	1.6	2.0	2.4	2.8	3.2
1N NaOH	0.17	0.23	0.29	0.35	0.40	0.46
Yellow pigment E 104 (Degussa AG, Düsseldorf, Germany)	0.34	0.45	0.59	0.69	0.80	0.91
PEG 6000	0.51	0.69	0.86	1.04	1.20	1.37

**Example 14: Differential Scanning Calorimetry (DSC)**

Differential scanning calorimetry (DSC) analyses were performed for determining the compatibility of different excipients for formulating tablets according to the present invention.

DSC is a thermoanalytical technique in which the difference in the amount of heat required to increase the temperature of a sample and reference is measured as a function of temperature. Both the sample and reference are maintained at nearly the same temperature throughout the experiment. Generally, the temperature program for a DSC analysis is designed such that the temperature increases or decreases linearly as a function of time.

The analyses were carried out employing a Netzsch DSC 204 apparatus (Netzsch Gerätebau GmbH, Selb, Germany). The heating rate used was 5 K/min up to a temperature of 300°C and the cooling rate was 1 K/min down to a temperature of -30°C. Temperature onset occurred at room temperature (approx. 20°C).

The below-mentioned samples were tested: crystalline 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine alone (black curves), the following excipients alone (red curves): lactose (Fig. 1A), crospovidone (Fig. 1B), starch 1500 (Fig. 1C), siliciumdioxide (Fig. 1D), as well as magnesium stearate (Fig. 1E), and binary mixtures of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine and each excipient (green curves).

As can be seen, siliciumdioxide does not show any interaction with 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine (i.e. represents an inert inorganic material), whereas lactose, crospovidone, and starch all show such interactions. Interactions were also detected when using microcrystalline cellulose, calciumphosphate, and

croscarmellose as excipients (data not shown). On the other hand, magnesium stearate and sodium stearyl fumarate dominate the thermogram.

**Example 15: Effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine in the treatment of prostate cancer**

Prostate cancer is a type of cancer developing in the prostate, a gland in the male reproductive system. Prostate cancer is most often discovered by physical examination or by screening blood tests, such as the PSA (prostate specific antigen) test. The PSA test measures the blood level of prostate-specific antigen, a serine protease similar to kallikrein. Its normal function is to liquefy gelatinous semen after ejaculation, allowing spermatazoa to more easily navigate through the uterine cervix. PSA levels above about 4 ng/ml are generally considered indicative for a risk to develop prostate cancer. However, PSA is not a perfect test and should thus be corroborated by additional analyses such as the detection of cell-associated PCA-3 mRNA in the urine.

The two most common treatments for locally-advanced or high risk prostate cancer are radiation therapy (RT) and androgen deprivation (AD), that is hormonal therapy. The effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine alone and in combination with RT, AD or RT+AD on the extent of programmed cell death (apoptosis) and the survival of prostate cancer cells were investigated, respectively.

First, the *in vitro* effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine, (ionizing) radiation, and a combination thereof on programmed cell death (apoptosis) and the survival rate of LNCaP androgen-sensitive human prostate adenocarcinoma cells were measured. The LNCaP cell line was established from a metastatic lesion of the adenocarcinoma. The cells were treated with a final concentration of 10  $\mu$ M 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine and (ionizing) radiation corresponding to an absorbed dose of 5 Gray units.

Apoptosis was determined using the Apo-ONE™ Homogenous Caspase-3/7 Assay, Promega, Inc., Madison, WI, USA according to the manufacturer's instructions. The percentage of living tumor cells was estimated by means of trypan blue dye  
5 exclusion as described (Freshney, R.I. (1994) *Culture of Animal Cells: A Manual of Basic Technique*. 3rd Ed. Wiley-Liss. New York. USA)

The cells were exposed to radiation six hours after (Fig. 3A), concomitantly with (Fig. 3B), or six hours before administration of 1-*O*-octadecyl-2-*O*-methyl-glycero-  
10 3-phospho-choline (Fig. 3C). The caspase assay was performed 12 hours after exposure to radiation. The respective data shown represent the average of two independent experiments.

When 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine was administered six  
15 hours prior to exposing the cells to radiation the combined treatment resulted in a survival of only about 45% of the tumor cells as compared to about 85% in untreated controls. Accordingly, in the treated cells a significant increase (> 2.5 fold) in apoptotic response was observed (as determined by the caspase-3/7 assay). Individual treatment with radiation or 1-*O*-octadecyl-2-*O*-methyl-glycero-3-  
20 phosphocholine resulted in intermediate survival rates of about 75% and about 60%, respectively (Fig. 3A).

In case of a concomitant administration of radiation and 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine to the cells the survival rate was determined to be about  
25 55%, which is in the same range as observed for the individual chemical treatment (about 50%). Exposure of the cells only to radiation resulted in a survival rate of about 80%, which is comparable to the untreated controls (about 86%). Surprisingly, the results of the caspase-3/7 assays were similar for the individual and the combined treatment (Fig. 3B).

- 34 -

When 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine was administered six hours after exposing the cells to radiation the combined treatment resulted in a survival of about 40% of the cells, which is in the same range as observed for the individual chemical treatment (about 45%). Exposure of the cells only to radiation  
 5 resulted in a survival rate of about 70%. The extent of apoptosis observed was about 25% increased in the cells only exposed to the chemical as compared to the cells exposed to the combined treatment (Fig. 3C).

Based on the above results it appears as if administration of 1-*O*-octadecyl-2-*O*-  
 10 methyl-glycero-3-phosphocholine prior to exposing the cells to radiation results in the most significant effect on cell survival rates and apoptotic response.

In a further approach, 10  $\mu$ M 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine (final concentration; "CHEM") and (ionizing) radiation (5 Gray units; "RT") were  
 15 administered simultaneously to the LNCaP cells but the subsequent incubation period was extended to 24 hours. Apoptosis was measured using the Apo-ONE™ Homogenous Caspase-3/7 Assay as described above and expressed as relative fluorescence units (RFLU). The percentage of apoptotic cells was determined by flow cytometric analysis of annexin V-PE positive-stained and 7-AAD (7-Amino  
 20 ActinomycinD) negative-stained cells (both purchased from BD Biosciences, San Jose, CA, USA) according to established standard protocols. The results are summarized in the following table. The data represent means  $\pm$  SEM from three independent experiments.

Treatment	% Annexin V-PE pos. cells	Caspase-3/7 activity (RFLU)
Control	3.6 $\pm$ 0.2	193 $\pm$ 39
CHEM	18.6 $\pm$ 1.0	580 $\pm$ 207
RT	5.0 $\pm$ 0.6	242 $\pm$ 36
CHEM+RT	31.7 $\pm$ 1.0*	1514 $\pm$ 102*

25

The statistical significance of the results was calculated using the one-way ANOVA, LSD test. \*  $p < 0.0001$  compared to each of the individual treatments CHEM and RT, respectively.

- 5 The enhancement of apoptosis in the "CHEM+RT" treated cells was also observed in androgen-insensitive LNCaP C4-2 and LNCaP-Res cells (data not shown).

Next, the interaction of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine administration ("CHEM") and androgen deprivation ("AD") was investigated.

- 10 LNCaP cells were deprived of androgen for two days by charcoal absorption of serum according to established procedures well known in the art. CHEM was added in a final concentration of 5  $\mu$ M and 10  $\mu$ M, respectively. In addition, it was tested whether addition of the synthetic androgen R1881 ("R1881") two days prior to CHEM administration resulted in reversal of the effect.

15

Apoptosis was measured using the Apo-ONE™ Homogenous Caspase-3/7 Assay as described above and expressed as relative fluorescence units (RFLU). The percentage of apoptotic cells was determined via annexin V-PE/7-AAD staining as described above. The caspase-3/7 assay and annexin staining were performed 22

- 20 hours after CHEM treatment. The results are summarized in the following table.

Treatment	% Annexin V-PE pos. cells	Caspase-3/7 activity (RFLU)
Contr.	9.6	235
Contr. + 5 $\mu$ M CHEM	13.0	380
Contr. + 10 $\mu$ M CHEM	17.5	436
AD	12.6	81
AD + 5 $\mu$ M CHEM	15.4	126
AD + 10 $\mu$ M CHEM	27.4	115
AD + R1881	7.0	130
AD + R1881 + 5 $\mu$ M CHEM	14.6	453
AD + R1881 + 10 $\mu$ M CHEM	21.6	962

- 36 -

Thus, administration of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine to androgen-deprived LNCaP cells resulted in a dose-dependent significant increase in apoptotic response. Furthermore, this effect was not reversed by adding a synthetic  
5 androgen to the medium prior to 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine treatment.

Additionally, in a preliminary study the *in vivo* effects of 1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine, (ionizing) radiation, and a combination thereof on LNCaP  
10 cells grown orthotopically in the prostates of nude mice (seven mice/ group) was investigated.

1-*O*-octadecyl-2-*O*-methyl-glycero-3-phosphocholine was administered intraperitoneally in a dose of 30 mg/kg body weight/day administered  
15 intraperitoneally for 15 days (Fig. 4A; studies using different routes of administration such as orally or by gavage are currently under way). The (ionizing) radiation corresponds to an absorbed dose of 5 Gray units administered on day 7 (Fig. 4B). The combined treatment is illustrated in Fig. 4C. Tumor growth was assessed via determining the serum level of the prostate-specific antigen (PSA) using a  
20 commercially available test kit as well as the tumor volume by means of magnetic resonance imaging.

As can be seen, the combined treatment resulted in a significant decrease of PSA serum levels as compared to either individual treatment ("PBS" represents  
25 phosphate-buffered saline) demonstrating that the *in vitro* results can also be transferred to an *in vivo* setting.

The present invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations, not specifically  
30 disclosed herein. Thus, for example, the terms "comprising", "including",

- 37 -

"containing", etc. shall be read expansively and without limitation. Additionally, the terms and expressions employed herein have been used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof,

5 but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the inventions embodied therein herein disclosed may be resorted to by those skilled in the art, and that such modifications and

10 variations are considered to be within the scope of this invention.

All documents cited or referenced herein including any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document referenced herein are hereby incorporated by reference,

15 and may be employed in the practice of the invention. Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.

The invention has been described broadly and generically herein. Each of the


20 narrower species and sub-generic groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein.

25 Other embodiments are within the following claims. In addition, where features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group.

**CLAIMS**

1. Pharmaceutical solid dosage form for oral administration comprising a tri-substituted glycerol compound according to formula (I)

5



or an enantiomer or diastereomer or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein

10

X is selected from the group consisting of phosphate and sulfate;

R<sub>1</sub> is selected from the group consisting of C<sub>16</sub>-C<sub>20</sub> alkyl;

R<sub>2</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl and C<sub>1</sub>-C<sub>3</sub> hydroxyalkyl;

R<sub>3</sub> is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>3</sub> alkyl;

15

R<sub>4</sub> is selected from the group consisting of C<sub>1</sub>-C<sub>3</sub> alkyl and C<sub>3</sub>-C<sub>6</sub> cycloalkyl; and

R<sub>5</sub> is selected from the group consisting of hydrogen and methyl.

2. The pharmaceutical solid dosage form according to claim 1, wherein X is phosphate, R<sub>1</sub> is -(CH<sub>2</sub>)<sub>17</sub>-CH<sub>3</sub>, R<sub>2</sub> is CH<sub>3</sub>, R<sub>3</sub> is H, R<sub>4</sub> is -(CH<sub>2</sub>)<sub>2</sub>-, and R<sub>5</sub> is CH<sub>3</sub>.

20

3. The pharmaceutical solid dosage form according to claim 1 or 2, wherein the tri-substituted glycerol compound is present in crystalline form.

- 39 -

4. The pharmaceutical solid dosage form according to any of claims 1 to 3, wherein the amount of the tri-substituted glycerol compound is in the range of 30 to 250 mg.
- 5 5. The pharmaceutical solid dosage form according to claim 4, wherein the amount of the tri-substituted glycerol compound is in the range of 50 to 150 mg.
6. The pharmaceutical solid dosage form according to any of claims 1 to 5,  
10 wherein the daily dosage of the tri-substituted glycerol compound is in the range of 50 to 350 mg.
7. The pharmaceutical solid dosage form according to any of claims 1 to 6,  
15 wherein the dosage form is selected from the group consisting of tablets, pills, capsules, and granules.
8. The pharmaceutical solid dosage form according to any of claims 1 to 7, wherein the dosage form is an enteric dosage form.
- 20 9. The pharmaceutical solid dosage form according to any of claims 1 to 8, wherein the dosage form is soluble at a  $\text{pH} \geq 5.5$ .
10. The pharmaceutical solid dosage form according to claim 9, wherein the dosage form is soluble at a  $\text{pH} \geq 6.8$ .
- 25 11. The pharmaceutical solid dosage form according to claim 9 or 10, wherein the dosage form according to U.S. Pharmacopoeia XXIX <701> disintegrates at a  $\text{pH}$  in the range of  $\geq 6.8$  within a contact time of at least 30 minutes.

- 40 -

12. The pharmaceutical solid dosage form according to any of claims 9 to 11, wherein the dosage form according to U.S. Pharmacopoeia XXIX <701> does not disintegrate at a pH in the range of  $\leq 2.5$  within a contact time of at least 120 minutes.
- 5
13. The pharmaceutical solid dosage form according to any of claims 1 to 12, wherein the dosage form comprises a film coating.
14. The pharmaceutical solid dosage form according to claim 13, wherein the
- 10 film coating is an enteric film coating.
15. The pharmaceutical solid dosage form according to claim 14, wherein the enteric film coating comprises at least one film forming material selected from the group consisting of acrylic resins, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, cellulose acetate
- 15 phthalate, and polyvinyl acetate phthalate acrylic resins, or mixtures thereof.
16. The pharmaceutical solid dosage form according to any of claims 13 to 15, wherein the film coating comprises at least one plasticizer.
- 20
17. The pharmaceutical solid dosage form according to claim 16, wherein the at least one plasticizer is selected from the group consisting of polyethylene glycol, polyethylene oxide, and triethyl citrate.
- 25
18. The pharmaceutical solid dosage form according to any of claims 1 to 17, wherein the at least one excipient comprises at least one each of the group consisting of fillers, binders, disintegrating agents, flowability-controlling agents, and lubricants.

19. The pharmaceutical solid dosage form according to claim 18, wherein the flowability-controlling agent is selected from the group consisting of disperse or colloidal silicon dioxide, magnesium stearate, calcium arachinate, cetyl alcohol, myristyl alcohol, and mixtures thereof.
- 5 20. The pharmaceutical solid dosage form according to claim 18 or 19, wherein the ratio between the tri-substituted glycerol compound and the at least one flowability-controlling agent is 1 part by weight of the tri-substituted glycerol compound to 0.01-0.1 parts by weight of the flowability-controlling agent.
- 10 21. The pharmaceutical solid dosage form according to any of claims 1 to 20, wherein the dosage form comprises at least one release-controlling agent.
- 15 22. The pharmaceutical solid dosage form according to any of claims 1 to 21, wherein the dosage form provides for immediate release of the tri-substituted glycerol compound.
- 20 23. The pharmaceutical solid dosage form according to any of claims 1 to 22, wherein at least 75% of the total amount of tri-substituted glycerol compound comprised in the dosage form is released from the dosage form within 45 minutes when measured in a type 1 dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXIX <724> at 37°C  $\pm$ 0.5°C in buffer state at pH 6.8 and 75 rotations per minute.
- 25 24. The pharmaceutical solid dosage form according to any of claims 1 to 23, wherein not more than 10% of the total amount of tri-substituted glycerol compound comprised in the dosage form is released from the dosage form within 2 hours when measured in a type 1 dissolution apparatus (paddle) according to U.S. Pharmacopoeia XXIX <724> at 37°C  $\pm$ 0.5°C in acidic state
- 30 at pH 1.2 and 75 rotations per minute.

- 42 -

25. Tri-substituted glycerol compound as defined in any of claims 1 to 24 for use as a pharmaceutical solid dosage form for oral administration.
26. The tri-substituted glycerol compound according to claim 25 for the treatment of cancer.
27. The tri-substituted glycerol compound according to claim 25 for the treatment of immune diseases.
28. Method for preparing a pharmaceutical solid dosage form according to any of claims 1 to 24, comprising:
- (a) mixing the tri-substituted glycerol compound with the at least one excipient.
29. The method according to claim 28, further comprising:
- (b) drying the mixture obtained in (a).
30. The method according to claim 28 or 29, further comprising:
- (c) granulating the mixture obtained in (a) or (b).
31. Method according to any of claims 28 to 30, wherein the residual moisture of the mixture after performing step (a) and/or (b) and/or (c) is less than 1.5% (w/w). based on the total weight of the mixture.
32. The method according to any of claims 28 to 31, further comprising:
- (d) compressing the mixture using a suitable tablet press.
33. The method according to claim 32, wherein compression is performed at a pressure of at least 200 MPa.




- 43 -

34. The method according to any of claims 28 to 33, further comprising:  
(e) coating the pharmaceutical formulation obtained with a film coating material.



- 5 35. Use of a pharmaceutical solid dosage form according to any of claims 1 to 24 as a medicament for the treatment of cancer.

36. Use of a pharmaceutical solid dosage form according to any of claims 1 to 24 as a medicament for the treatment of immune diseases.

1/6


**FIG. 1****A****B****C**

2/6

**FIG. 1 (cont.)****D****E**

## FIG. 2

**A**



**B**






FIG. 3


A






B



5/6

**FIG. 3 (cont.)****C**

6/6

**FIG. 4****A****30 mg 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine****B****30 mg 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine  
+ 5 Gy radiation****C****PBS + 5 Gy radiation**

# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/062180

**A. CLASSIFICATION OF SUBJECT MATTER**  
INV. A61K9/28 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 198 22 509 A1 (MEDMARK PHARMA GMBH [DE]) 25 November 1999 (1999-11-25) claims 1,5	1-26, 28-35
X	WO 99/30690 A (AXIA THERAPEUTICS INC [US]; COMPTON BRUCE JON [US]; SOLARI NANCY E [US] 24 June 1999 (1999-06-24) claims 1,22,27,34,36	1,2,7,8, 25,26, 28-35
X	US 2004/138263 A1 (D ANGIO PAUL [US] ET AL) 15 July 2004 (2004-07-15) paragraphs [0028], [0029], [0064]; claim 1	1-26, 28-35
	-/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 April 2008

Date of mailing of the international search report

17/04/2008

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040; Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Giese, Hans-Hermann

# INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2007/062180

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PINCHUK A N ET AL: "SYNTHESIS OF ALKYL GLYCEROPHOSPHOLIPIDS THROUGH 1-O-BENZYL-2-O-METHYL-rac-GLYCEROL" PHARMACEUTICAL CHEMISTRY JOURNAL, CONSULTANTS BUREAU, NAW YORK, NY, US, vol. 26, 1992, pages 174-176, XP008087544 ISSN: 0091-150X the whole document	1,2,35
A	WO 90/14829 A (MAX PLANCK GESELLSCHAFT [DE]) 13 December 1990 (1990-12-13) page 3, paragraph 2 - page 4 page 12, paragraph 1 page 15; table 1	1-36

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2007/062180

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 35 and 36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers allsearchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search reportcovers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2007/062180

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 19822509	A1	25-11-1999	AT 223721 T 15-09-2002
		WO 9959599 A1	25-11-1999
		EP 1079838 A1	07-03-2001
		JP 2002515439 T	28-05-2002
		US 6514519 B1	04-02-2003
WO 9930690	A	24-06-1999	AU 1827799 A 05-07-1999
US 2004138263	A1	15-07-2004	US 2006216344 A1 28-09-2006
WO 9014829	A	13-12-1990	AU 5670690 A 07-01-1991
		CA 2056421 A1	03-12-1990
		CS 9002689 A3	15-01-1992
		DE 3918082 A1	24-01-1991
		DK 474712 T3	29-11-1993
		EP 0474712 A1	18-03-1992
		ES 2060173 T3	16-11-1994
		GR 90100406 A	15-11-1991
		IE 64039 B1	28-06-1995
		JP 2977894 B2	15-11-1999
		JP 4507096 T	10-12-1992
		US 5266564 A	30-11-1993
		ZA 9004196 A	27-03-1991